Skip to main navigation
Skip to search
Skip to main content
Maastricht University Home
Support & FAQ
Link opens in a new tab
Search content at Maastricht University
Home
Researchers
Publications
Activities
Press/Media
Prizes
Organisations
Dataset/Software
Projects
Safety of thiopurines in the treatment of inflammatory bowel disease
D J de Jong
,
L J J Derijks
, A H J Naber
, P M Hooymans
, C J J Mulder
Research output
:
Contribution to journal
›
(Systematic) Review article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Safety of thiopurines in the treatment of inflammatory bowel disease'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Inflammatory Bowel Disease
100%
Thiopurines
100%
Dose-independent
75%
Adverse Events
50%
Therapeutic Drug Monitoring
50%
Reduced Toxicity
50%
6-mercaptopurine (6-MP)
50%
Dose-dependent
50%
Fever
25%
Skin Rash
25%
Metabolism
25%
Clinical Trials
25%
Prospective Randomized Trial
25%
Clinical Significance
25%
Diarrhea
25%
Hepatotoxicity
25%
Nausea
25%
Prodrug
25%
Medical Therapy
25%
Pancreatitis
25%
Myelotoxicity
25%
Idiosyncratic Reaction
25%
Thiopurine Methyltransferase
25%
Malaise
25%
6-thioguanine nucleotides
25%
6-thioguanine (6-TG)
25%
Poor Metabolizer
25%
INIS
diseases
100%
doses
100%
safety
100%
inflammation
100%
toxicity
66%
drugs
50%
patients
33%
monitoring
33%
mercaptopurine
33%
skin
16%
fever
16%
values
16%
therapy
16%
side effects
16%
clinical trials
16%
reviews
16%
metabolism
16%
nucleotides
16%
enzymes
16%
diarrhea
16%
nausea
16%
methyl transferases
16%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Bowel Disease
100%
Mercaptopurine
100%
Adverse Event
33%
Azathioprine
33%
Tioguanine
33%
Therapeutic Drug Monitoring
33%
Enzymes
16%
Clinical Trial
16%
Diarrhea
16%
Hepatotoxicity
16%
Nausea
16%
Malaise
16%
Pancreatitis
16%
Rash
16%
Bone Marrow Toxicity
16%
Thiopurine Methyltransferase
16%
Prodrug
16%
Side Effect
16%